---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-000715"
form_type: "8-K"
ticker: "FENC"
cik: "0001211583"
company_name: "FENNEC PHARMACEUTICALS INC."
filed_at: "2025-02-07T23:59:59+00:00"
generated_at: "2026-05-27T00:50:20.583370+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Fennec's partner Norgine launches PEDMARQSI in Germany for cisplatin-induced hearing loss prevention

## Summary
- PEDMARQSI (sodium thiosulfate injection) launched in Germany by Norgine for prevention of ototoxicity in pediatric patients.
- First and only approved therapy in EU/UK for cisplatin-induced hearing loss in children 1 month to <18 years with localized solid tumors.
- License deal (March 2024) included $43M upfront, up to $230M in milestones, and double-digit tiered royalties (mid-teens to mid-twenties).
- Phase 3 data showed ~50% reduction in hearing loss vs. cisplatin alone.

## SEC filing metadata
- accession: 0001558370-25-000715
- form_type: 8-K
- ticker: FENC
- cik: 0001211583
- company_name: FENNEC PHARMACEUTICALS INC.
- filed_at: 2025-02-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1211583/000155837025000715/0001558370-25-000715-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1211583/000155837025000715/fencf-20250207x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-000715
- JSON: https://secwatch.observer/filing/0001558370-25-000715.json
- Plain text: https://secwatch.observer/filing/0001558370-25-000715.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.